Repare Therapeutics (NASDAQ:RPTX) Receives Market Perform Rating from Lifesci Capital

Repare Therapeutics (NASDAQ:RPTX)‘s stock had its “market perform” rating reaffirmed by stock analysts at Lifesci Capital in a research report issued on Friday,Benzinga reports.

A number of other analysts also recently weighed in on RPTX. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Repare Therapeutics in a report on Friday, November 8th. Stifel Nicolaus decreased their target price on Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday.

Repare Therapeutics Price Performance

Shares of NASDAQ RPTX traded down $2.24 during trading hours on Friday, hitting $1.73. 4,121,994 shares of the stock were exchanged, compared to its average volume of 189,039. Repare Therapeutics has a one year low of $1.66 and a one year high of $8.49. The company’s 50 day moving average is $3.34 and its 200 day moving average is $3.36. The firm has a market capitalization of $73.54 million, a P/E ratio of -0.88 and a beta of 0.71.

Institutional Investors Weigh In On Repare Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vontobel Holding Ltd. lifted its stake in Repare Therapeutics by 20.0% in the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after buying an additional 4,000 shares during the period. Bank of Montreal Can raised its position in shares of Repare Therapeutics by 5.4% in the 2nd quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock valued at $366,000 after acquiring an additional 5,673 shares during the period. Barclays PLC boosted its stake in Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company’s stock worth $29,000 after acquiring an additional 7,800 shares during the last quarter. Exchange Traded Concepts LLC grew its holdings in Repare Therapeutics by 21.2% during the third quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock valued at $174,000 after purchasing an additional 8,809 shares during the period. Finally, Stifel Financial Corp increased its stake in Repare Therapeutics by 36.4% in the third quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock valued at $178,000 after purchasing an additional 13,800 shares in the last quarter. 85.09% of the stock is owned by institutional investors and hedge funds.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.